Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Dinesh V. Patel Ph.D. | CEO, President, Secretary & Director | 1.03M | -- | 1957 |
| Mr. Matthew M. Gosling J.D. | Executive VP & General Counsel | -- | -- | 1971 |
| Ms. Carena Spivey | Head of HR & Senior VP of Human Resources | -- | -- | -- |
| Dr. Ashok Bhandari Ph.D. | Executive VP & Chief Drug Discovery and Preclinical Development Officer | -- | -- | 1964 |
| Mr. Carter J. King | Executive Vice President of Business Development | -- | -- | 1971 |
| Dr. Arturo M. Molina FACP, M.D., M.S. | Chief Medical Officer | -- | -- | 1959 |
| Dr. Samuel R. Saks M.D. | Clinical Development Advisor | -- | -- | 1955 |
Protagonist Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 126
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Corporate Governance
Upcoming Events
May 5, 2025 at 8:00 PM UTC - May 9, 2025 at 8:00 PM UTC
Protagonist Therapeutics, Inc. Earnings Date